Search results
Watmind USA™ Receives FDA Emergency Use Authorization for SpeedySwab™ 15-Minute At-Home 3-in-1...
The Tomahawk· 5 days agoWatmind USA™, a leader in providing health diagnostic testing solutions, proudly announces that it...
FDA grants EUA for Watmind USA’s SpeedySwab Covid + FLU A&B self-test
Medical Device Network via Yahoo Finance· 2 days agoWatmind USA has been granted Emergency Use Authorization (EUA) by the US Food and Drug...
FDA Panel to Consider Which COVID Strain to Target in an Updated Vaccine
MedPage Today· 2 days agoIn the briefing document, the FDA staff gave a brief history of coronavirus vaccines, noting that...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 5 days agoFood and Drug Administration (FDA) on an expedient, repeatable immunobridging pathway to future potential emergency use authorizations ...
Invivyd aligns with FDA on rapid mAb trial pathway By Investing.com
Investing.com· 5 days agoFood and Drug Administration (FDA) on a new clinical trial pathway for the expedited development of...
Designating a Platform Technology: FDA’s Long-Awaited Draft Guidance | JD Supra
JD Supra· 7 days agoIn newly released Draft Guidance from the U.S. Food and Drug Administration (FDA) entitled, Platform Technology Designation Program for Drug Development, the FDA& ...
QIAGEN (QGEN) Develops Test for Research and CDx Application
Zacks via Yahoo Finance· 5 days agoQIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid...
Get Your Free 2024 Mpox Vaccine, Say San Francisco Health Officials | KQED
KQED· 6 days agoSFDPH said that previous mpox outbreaks have predominantly affected communities of gay and bisexual...
Invivyd appoints new Chief Commercial Officer ahead of PEMGARDA launch By Investing.com
Investing.com· 5 days agoInvivyd, Inc. (NASDAQ:IVVD), a company focused on developing treatments for viral infectious...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 1 day agoNeoImmuneTech's NT-I7 has shown potential in nonclinical studies to address the immunosuppressive effects of ARS. ROCKVILLE, Md. , June 4, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech ...